BackSAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Overview
SAB Biotherapeutics Inc - Unit (1 Ordinary share & 1/2 Wrt)

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Return on Equity

Valuation check: BCYPU's ROE is -5.95%, below the sector sector average of -5.72%.

Get informed when a big investor buys or sells

+ Follow

ROE

-5.95%

Return on Equity

-5.95%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) (BCYPU) FAQ

As of the most recent data, BCYPU shows a ROE of -5.95%. That is below the sector sector average of -5.72%. Scroll down for historical charts and peer comparison views.

The its sector sector average ROE is about -5.72%. SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is at -5.95%, which is lower that average. That is roughly 3.9% below the sector mean. Use the comparison chart on this page to see how BCYPU stacks up against individual peers as well.

Check the historical chart to see whether BCYPU's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -5.95%) with ownership activity and broader fundamentals.